Key result
SGLT2 inhibitors cut HF and renal events, whereas GLP-1 agonists reduce ischemic risk.
Why the study?
Multiple recent cardiovascular outcomes trials have evaluated SGLT2 inhibitors and GLP-1 receptor agonists, making it important to examine their cardiovascular benefits and potential side effects in patients with type 2 diabetes mellitus.
Do sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists reduce cardiovascular events and heart failure hospitalizations compared with placebo in patients with type 2 diabetes?
Do sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists reduce cardiovascular events and heart failure hospitalizations compared with placebo in patients with type 2 diabetes?
This review summarizes landmark CVOTs showing that in patients with type 2 diabetes, SGLT2 inhibitors robustly reduce heart failure hospitalization and renal progression while GLP-1 receptor agonists predominantly reduce atherosclerotic ischemic events, supporting tailored therapy selection based on predominant cardiovascular or renal comorbidities.
Answers are grounded in this paper and cite their sources.
May guide SGLT2 inhibitor or GLP-1 agonist selection by HF/renal versus ischemic risk; leaves open head-to-head comparative trials.
PURPOSE OF REVIEW: In recent years, there have been several cardiovascular outcomes trials (CVOT) of two new classes of glucose-lowering medications: sodium-glucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA). It is important examine their potential for cardiovascular benefit and possible side effects among patients with type 2 diabetes (T2D) mellitus. RECENT FINDINGS: The current article reviews the findings of recent CVOT of SGLT2-i and GLP-1 RA, including their impact on cardiovascular events and relevant side effects. SUMMARY: For all T2D patients, with or without established cardiovascular disease, the SGLT2-i have demonstrated impressive reductions in hospitalization for heart failure and renoprotection. For T2D patients with established cardiovascular disease, SGLT2-i demonstrated an additional benefit of reduced major adverse cardiac events, on top of reductions in hospitalizations for heart failure, renoprotection, and in some instances, mortality. Similarly, all GLP-1 RA CVOTs demonstrated noninferiority compared with placebo for safety. In comparison, GLP-1 RA appear to preferentially reduce ischemic events (stroke or myocardial infarction) over hospitalization for heart failure, and demonstrated renoprotection in several of the CVOTs.
No takes yet. Share an insight, caveat, or question.
North et al. (2019) conducted a review in Type 2 diabetes mellitus with or without established cardiovascular disease. Sodium-glucose cotransporter-2 inhibitors (empagliflozin, canagliflozin, dapagliflozin) and glucagon-like peptide-1 receptor agonists (lixisenatide, liraglutide, semaglutide, exenatide, albiglutide, dulaglutide) vs. Placebo was evaluated on Major adverse cardiac events (MACE-3: composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke) and hospitalization for heart failure. SGLT2 inhibitors reduce heart failure hospitalization and renal events in type 2 diabetes, whereas GLP-1 receptor agonists preferentially reduce ischemic events such as stroke and myocardial infarction.
Synapse has enriched 10 related papers. Consider them for comparative context: